Clinical Observation Of Transfer Factor Injection Combined With Cryotherapy In The Treatment Of Recurrent Condyloma Acuminatum

Objective:To observe the clinical efficacy and recurrence rate of transfer factor injection combined with cryotherapy in the treatment of recurrent condyloma acuminatum,and to observe the changes of CD4~+,CD8~+,CD4/CD8 T lymphocytes and local HPV(human papilloma virus)subtypes before and after treatment.To explore the advantages of transfer factor injection combined with cryotherapy in the treatment of recurrent condyloma acuminatum compared with thymopentin combined with cryotherapy and simple cryotherapy.Methods:Data were collected from patients with recurrent condyloma acuminatum treated at our dermatology clinic between December 2021 and March 2022.The 105 patients who met the inclusion criteria were randomised into a transfer factor group,a thymopentin group and a cryotherapy group,each with 35 cases.The transfer factor group received a local injection of transfer factor at a dose of 2.5 ml per injection once weekly for 10 weeks after cryotherapy,while the thymopentin group received a topical injection of thymopentin at a dose of 2.5 ml per injection once weekly for 10 weeks after cryotherapy.In the cryotherapy group,lesions were cryotherapy once a week for a total of 10 weeks.If the warts recur during the follow-up period,cryotherapy will be performed to remove the visible warts and the initial injection will be continued until the end of the treatment.The clinical effectiveness and relapse rate of the three groups will be calculated,as well as the effects on T lymphocyte subpopulations and local lesion HPV subtypes before and 1 week after the last treatment,while the incidence of adverse events,treatment costs and follow-up will be recorded during treatment.Results:1.After treatment,33,32 and 33 patients were included in the transfer factor group,thymopentin group and cryotherapy group,respectively.There were no statistically significant differences between sex,age,disease course,lesion site,number of warts,CD4~+,CD8~+,CD4/CD8 and HPV subtypes before treatment(P>0.05).2.After treatment,the clinical effectiveness of the three groups were 90.91%in the transfer agent group,87.50%in the thymopentin group and 36.36%in the cryotherapy group.The effective rates of the three groups were statistically analyzed,statistically significant(P<0.05).3.After treatment,the recurrence rate at 3-month Tracking in the three cured groups were 0.00%(0/16)in the transfer factor group,5.26%(2/19)in the thymopentin group and 85.71%(6/7)in the cryotherapy group,respectively.statistically significant(P<0.05).4.After treatment,CD4~+,CD8~+and CD4/CD8 differences between the three groups were statistically significant(P<0.05),and when comparing the groups,statistically significant differences were found between the transfer factor and thymopentin groups compared to the cryotherapy group(P<0.05).Comparing CD4~+,CD8~+and CD4/CD8 before and after treatment in each group,the difference before and after treatment in the transfer factor and thymopentin groupswas statistically significant(P<0.05),while the difference in the cryotherapy group was not statistically significant(P>0.05),and the difference in the transfer factor and thymopentin groups was statistically significant compared with the cryotherapy group.5.After treatment,the decrease rate of HPV subtypes in local lesions of the three groups was 60.06%in the transfer factor group,56.25%in the thymopentin group,and 15.15%in the cryotherapy group,respectively,statistically significant(P<0.05).6.No serious adverse events occurred during treatment in any of the three groups,the difference in adverse event rates among each group was not statistically significant(P>0.05).7.The total cost of treatment in the three groups was higher in the thymopentin group than in the cryotherapy group,and higher in the cryotherapy group than in the transfer factor group,and the difference was statistically significant(P<0.05).Conclusion:Transfer factor injection combined with cryotherapy is comparableto topical injection of lymopentin combined with cryotherapy in terms of overall efficacy,recurrence rate and impact on CD4~+,CD8~+,CD4/CD8 and HPV reduction rates,but compared to the cryotherapy group,it can significantly improve clinical efficacy in CA patients,reduce recurrence rate,regulate T lymphocyte sub population levels and induce relative reduction of HPV subtypes in localized lesions.Treatment costs are lower than for thymopentin and adverse reactions are fewer,which is worth further promotion and research.